Early diagnosis of cancer is one of the highest-priority problem for the healthcare system, because it is critical for overall treatment success and saving patients' lives. Diffusion-weighted magnetic resonance imaging (DWI) may be used to detect a malignancy in various tissues and organs. It has the advantage of providing insight into the diffusion of water molecules in body tissues without exposing patients to radiation.

DWI of the phantom with polyvinylpyrrolidone (PVP) solutions (b value 500 s/mm2). Image courtesy of Kristina Sergunova et al.


June 2, 2020 — Early diagnosis of cancer is one of the highest-priority problem for the healthcare system, because it is critical for overall treatment success and saving patients' lives. Diffusion-weighted magnetic resonance imaging (DWI) may be used to detect a malignancy in various tissues and organs. It has the advantage of providing insight into the diffusion of water molecules in body tissues without exposing patients to radiation.

The way the H2O molecules move depends on whether they are inside or outside the cells. Inside the cell the water movement is somewhat restricted by organelles that sometimes get in the way (slow diffusion) and semi-permeable cell membranes (hindered diffusion). Since in-between the cells there is more room, the only thing that restrict the water movement is cell membrane.

Such movement can be estimated through the mathematical processing of DWI data using apparent diffusion coefficient (ADC) maps. In absence of pathological tissues the intracellular ADC is lower compared to intercellular ADC. However, an increase in cell density (in presence of malignancies, especially those made up of many small-size cells) leads to a decrease in intercellular diffusion.

Since ACD is not an absolute value, it makes it dependable on external factors, such as sequence and reconstruction parameters, image quality and hardware features. In order to boost the efficacy of tumor differential diagnostics ACD must be estimated with greater accuracy and reproducibility. This can be achieved with phantoms (also called test objects) that allow assessing the imaging quality and building various diffusion models (i.e. non-restricted, hindered, and restricted diffusion with permiable and semi-permiable membranes). Such phantom has been developed by a research team from the Innovation Technology Department of the Moscow Center for Diagnostics & Telemedicine.

The scope of application of the phantoms developed by the US National Institute of Standards and Technology, the Quantitative Imaging Biomarkers Alliance and the Institute of Cancer Research in the UK is limited because they utilize polymer solutions. Instead, the authors of this paper suggested using a combination of siloxane-based water-in-oil (W/O) emulsions and aqueous solutions of polyvinylpyrrolidone (PVP). This components allow emulating both hindered and restricted diffusion while maintaining relatively high signal intensity. What is more, the newly-designed phantom can be used to assess the image quality control in terms of fat suppression, which again is critical for detecting pathological processes.

To simulate hindered diffusion, the investigators used aqueous PVP solutions with concentrations of 0 to 70%. The W/O emulsions imitated restricted diffusion in intracellular space. To attain high DWI signal (maximum radiolucent areas), the authors incorporated silicone oil: cyclomethicone and caprylyl-methicone. This phantom was scanned using 1.5T magnetic resonance scanner with various fat suppression techniques.

After a series of control experiments the authors came to a conclusion, that such phantom with the control substances allows modelling the apparent diffusion coefficients ranging from normal tissue to benign and malignant lesions: from 2.29 to 0.28mm2/s. Correspondingly, it is suitable for assessing the ACD measurement quality and the efficacy of fat suppression, as well as for calibrating MR scanners from varioous manufacturers.

This study is a part of the bigger research project started in the Moscow Center for Diagnostics & Telemedicine in 2017, that addresses standardization and optimization of MR scanners. The project is also aimed at developing the means of control over the scanner parameters to secure the high image quality and increase the diagnostic value of imaging studies.

For more information: medradiology.moscow


Related Content

News | Magnetic Resonance Imaging (MRI)

Jan. 27, 2026 — Hyperfine has announced results from the largest data set to date evaluating stroke detection with its ...

Time January 28, 2026
arrow
News | Radiology Education

Jan. 22, 2026—The American Roentgen Ray Society (ARRS) will host a live virtual symposium, "Medical Imaging for ...

Time January 28, 2026
arrow
News | Radiology Imaging

Jan.26, 2026 — SimonMed Imaging has unveiled an updated brand and the launch of SimonMed Longevity, a new division ...

Time January 27, 2026
arrow
News | PET Imaging

Jan. 26, 2026 — Nuclidium, a clinical-stage radiopharmaceutical company developing a proprietary copper-based ...

Time January 27, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

Jan. 20, 2026 — Hyperfine, the developer of the first FDA-cleared AI-powered portable MRI system for the brain — the ...

Time January 20, 2026
arrow
News | Radiation Therapy

Jan. 16, 2026 — Elekta has announced that its Elekta Evo* CT-Linac has received 510(k) clearance from the U.S. Food and ...

Time January 16, 2026
arrow
News | Stroke

Dec. 12, 2025 — Hyperfine, Inc. has announced that it has received FDA clearance for a new multi-direction diffusion ...

Time December 15, 2025
arrow
News | Artificial Intelligence

Dec. 1, 2025 — Researchers at the University of California, Berkeley and University of California, San Francisco have ...

Time December 10, 2025
arrow
Feature | Uzay Emir and Stephen Sawiak

Healthcare has reached a critical juncture. The World Economic Forum estimates that global medical costs will see double ...

Time December 04, 2025
arrow
News | FDA

Dec. 02, 2025 — Alpha Tau Medical Ltd., the developer of the alpha-radiation cancer therapy Alpha DaRT, has announced ...

Time December 04, 2025
arrow
Subscribe Now